Giuseppe Curigliano

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 17 papers. Top paper: “Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial”.

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30321-1

N/A

5.7DataRank · unranked

527 citations

Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle +14 more

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Nature Medicine(2022)10.1038/s41591-022-01931-y

N/A

3.9DataRank · unranked

240 citations

Philippe A. Cassier, Salvatore Siena, Elena Garralda, Luis Paz‐Ares, Pilar Garrido +14 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

European Heart Journal(2021)10.1093/eurheartj/ehab674

N/A

0.966DataRank · unranked

625 citations

Daniel J. Lenihan, Saro H. Armenian, Ana Barac, Anne Blaes, Daniela Cardinale +22 more

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

npj Breast Cancer(2020)10.1038/s41523-020-0156-0

N/A

0.801DataRank · unranked

208 citations

Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen +95 more

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Annals of Oncology(2022)10.1016/j.annonc.2022.08.002

N/A

0.782DataRank · unranked

183 citations

Giuseppe Curigliano, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S.W. Tan +21 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0.742DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102410

N/A

0.612DataRank · unranked

58 citations

Marisa Cobanaj, Federica Marian, Edward Christopher Dee, Maxwell R. Lloyd, Sara Marcu +6 more

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

ESMO Open(2024)10.1016/j.esmoop.2024.102388

N/A

0.442DataRank · unranked

18 citations

Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés +15 more

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy

Breast Cancer Research(2025)10.1186/s13058-025-02020-x

N/A

0.360DataRank · unranked

10 citations

Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli +21 more

Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences

Breast Cancer Research and Treatment(2025)10.1007/s10549-024-07595-1

N/A

0.269DataRank · unranked

5 citations

Paola Zagami, Marzia Del Re, Carmen Criscitiello, Antonio Marra, Giuseppe Curigliano +1 more

Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow

European Journal of Cancer(2023)10.1016/j.ejca.2023.113504

N/A

0DataRank · unranked

11 citations

Chiara Corti, Edward Christopher Dee, Lucas McCullum, Laura Boldrini, Ilana Schlam +5 more

Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Cancer(2024)10.1002/cncr.35323

N/A

0DataRank · unranked

20 citations

Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio Di Meglio +40 more

Effect of the COVID-19 pandemic on cancer treatment and research

The Lancet Haematology(2020)10.1016/s2352-3026(20)30123-x

N/A

0DataRank · unranked

161 citations

Begoña de las Heras, JAVIER DE CASTRO, Ramachandran Venkitaraman, Martine Poelman, Gopalakrishnan Srinivasan +6 more

Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers

Nature Communications(2020)10.1038/s41467-020-16243-3

N/A

0DataRank · unranked

156 citations

Franca Raucci, Claudio Vernieri, Irene Caffa, Roberta Buono, Maura Fanti +6 more